Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 8/2017

01-08-2017 | Review Article

Beneficial effects of ketogenic diets for cancer patients: a realist review with focus on evidence and confirmation

Author: Rainer J. Klement

Published in: Medical Oncology | Issue 8/2017

Login to get access

Abstract

Ketogenic diets (KDs) have gained popularity among patients and researchers alike due to their putative anti-tumor mechanisms. However, the question remains which conclusions can be drawn from the available human data thus far concerning the safety and efficacy of KDs for cancer patients. A realist review utilizing a matrix analytical approach was conducted according to the RAMESES publication standards. All available human studies were systematically analyzed and supplemented with results from animal studies. Evidence and confirmation were treated as separate concepts. In total, 29 animal and 24 human studies were included in the analysis. The majority of animal studies (72%) yielded evidence for an anti-tumor effect of KDs. Evidential support for such effects in humans was weak and limited to individual cases, but a probabilistic argument shows that the available data strengthen the belief in the anti-tumor effect hypothesis at least for some individuals. Evidence for pro-tumor effects was lacking completely. Feasibility of KDs for cancer patients has been shown in various contexts. The probability of achieving an anti-tumor effect seems greater than that of causing serious side effects when offering KDs to cancer patients. Future controlled trials would provide stronger evidence for or against the anti-tumor effect hypothesis.
Appendix
Available only for authorised users
Footnotes
1
As most philosophers of science, Carnap [16] who formulated this principle made no clear distinction between evidence, data and confirmation [15]. Within our framework (see Materials and Methods section), his principle of total evidence would better be described as the principle to consider all relevant available data when making inferences about hypotheses.
 
2
A distinction should be made between “fundamentalist” skepticism, a term coined by M.M. Ćirković [125] and other, more rational forms of skepticism that for example acknowledge the mechanistic data, but consider the human data not supportive for methodological reasons. Examples of the former have been critisized by us previously [117, 126].
 
Literature
1.
Paoli A, Rubini A, Volek JS, Grimaldi KA. Beyond weight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets. Eur J Clin Nutr. 2013;67:789–96.PubMedPubMedCentralCrossRef
2.
Seyfried TN, Flores RE, Poff AM, D’Agostino DP. Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis. 2014;35:515–27.PubMedCrossRef
3.
Vidali S, Aminzadeh S, Lambert B, Rutherford T, Sperl W, Kofler B, et al. Mitochondria: the ketogenic diet—a metabolism-based therapy. Int J Biochem Cell Biol. 2015;63:55–9.PubMedCrossRef
4.
Seyfried TN, Yu G, Maroon JC, D’Agostino DP. Press-pulse: a novel therapeutic strategy for the metabolic management of cancer. Nutr Metab (Lond). 2017;14:19.CrossRef
5.
Klement RJ, Kämmerer U. Is there a role for carbohydrate restriction in the treatment and prevention of cancer? Nutr Metab (Lond). 2011;8:75.CrossRef
6.
Allen BG, Bhatia SK, Anderson CM, Eichenberger-Gilmore JM, Sibenaller ZA, Mapuskar KA, et al. Ketogenic diets as an adjuvant cancer therapy: history and potential mechanism. Redox Biol. 2014;2C:963–70.CrossRef
7.
Klement RJ, Champ CE. Calories, carbohydrates, and cancer therapy with radiation: exploiting the five R’s through dietary manipulation. Cancer Metasta Rev. 2014;33:217–29.CrossRef
8.
Woolf EC, Syed N, Scheck AC. Tumor metabolism, the ketogenic diet and β-hydroxybutyrate: novel approaches to adjuvant brain tumor therapy. Front Mol Neurosci. 2016;9:122.PubMedPubMedCentralCrossRef
9.
Winter SF, Loebel F, Dietrich J. Role of ketogenic metabolic therapy in malignant glioma: a systematic review. Crit Rev Oncol Hematol. 2017;112:41–58.PubMedCrossRef
10.
Huebner J, Marienfeld S, Abbenhardt C, Ulrich C, Muenstedt K, Micke O, et al. Counseling patients on cancer diets: a review of the literature and recommendations for clinical practice. Anitcancer Res. 2014;34:39–48.
11.
Howick J. The philosophy of evidence-based medicine. 1st ed. Oxford: Wiley; 2011.CrossRef
12.
Walach H, Falkenberg T, Fønnebø V, Lewith G, Jonas WB. Circular instead of hierarchical: methodological principles for the evaluation of complex interventions. BMC Med Res Methodol. 2006;6:29.PubMedPubMedCentralCrossRef
13.
Walach H, Loef M. Using a matrix-analytical approach to synthesizing evidence solved incompatibility problem in the hierarchy of evidence. J Clin Epidemiol. 2015;68:1251–60.PubMedCrossRef
14.
Tan-Shalaby JL, Carrick J, Edinger K, Genovese D, Liman AD, Passero VA, et al. Modified Atkins diet in advanced malignancies: final results of a safety and feasibility trial within the Veterans Affairs Pittsburgh Healthcare System. Nutr Metab (Lond). 2016;13:52.CrossRef
15.
Bandyopadhyay PS, Brittan G Jr, Taper ML. Belief, evidence, and uncertainty: problems of Epistemic inference. 1st ed. Berlin: Springer Nature; 2016.CrossRef
16.
Carnap R. On the application of inductive logic. Philos Phenomenol Res. 1947;8:133–48.CrossRef
17.
Pawson R, Greenhalgh T, Harvey G, Walshe K. Realist review–a new method of systematic review designed for complex policy interventions. J Health Serv Res Policy. 2005;10:21–34.PubMedCrossRef
18.
Greenhalgh T, Wong G, Westhorp G, Pawson R. Protocol–realist and meta-narrative evidence synthesis: evolving standards (RAMESES). BMC Med Res Methodol. 2011;11:115.PubMedPubMedCentralCrossRef
19.
20.
Aronson JL. A realist philosophy of science. 1st ed. London: The Macmillan Press Ltd; 1984.CrossRef
21.
Pérez-Guisado J, Muñoz-Serrano A, Alonso-Moraga Á. Spanish Ketogenic Mediterranean diet: a healthy cardiovascular diet for weight loss. Nutr J. 2008;7:30.PubMedPubMedCentralCrossRef
22.
Clemens Z, Kelemen A, Fogarasi A, Tóth C. Childhood absence epilepsy successfully treated with the Paleolithic Ketogenic diet. Neurol Ther. 2013;2:71–6.PubMedPubMedCentralCrossRef
23.
Nebeling LC, Lerner E. Implementing a ketogenic diet based on medium-chain triglyceride oil in pediatric patients with cancer. J Am Diet Assoc. 1995;95:693–7.PubMedCrossRef
24.
Jenkins DJA, Wong JMW, Kendall CWC, Esfahani A, Ng VWY, Leong TCK, et al. The effect of a plant-based low-carbohydrate (“Eco-Atkins”) diet on body weight and blood lipid concentrations in hyperlipidemic subjects. Arch Intern Med. 2009;169:1046–54.PubMedCrossRef
25.
Walach H. Mehr Daten? Mehr denken? Umdenken! Forschende Komplementärmedizin/Res Complement Med. 2016;23:3–5.CrossRef
26.
Fearon KC, Borland W, Preston T, Tisdale MJ, Shenkin A, Calman KC. Cancer cachexia: influence of systemic ketosis on substrate levels and nitrogen metabolism. Am J Clin Nutr. 1988;47:42–8.PubMed
27.
Nebeling L, Miraldi F, Shurin S, Lerner E. Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J Am Coll Nutr. 1995;14:202–8.PubMedCrossRef
28.
Chu-Shore CJ, Thiele EA. Tumor growth in patients with tuberous sclerosis complex on the ketogenic diet. Brain Dev. 2010;32:318–22.PubMedCrossRef
29.
Schmidt M, Pfetzer N, Schwab M, Strauss I, Kämmerer U. Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: a pilot trial. Nutr Metab (Lond). 2011;8:54.CrossRef
30.
Schroeder U, Himpe B, Pries R, Vonthein R, Nitsch S, Wollenberg B. Decline of lactate in tumor tissue after ketogenic diet: in vivo microdialysis study in patients with head and neck cancer. Nutr Cancer. 2013;65:843–9.PubMedCrossRef
31.
Champ CE, Palmer JD, Volek JS, Werner-Wasik M, Andrews DW, Evans JJ, et al. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. J Neurooncol. 2014;117:125–31.PubMedCrossRef
32.
Branca JJV, Pacini S, Ruggiero M. Effects of Pre-surgical vitamin D supplementation and Ketogenic Diet in a patient with recurrent breast cancer. Anticancer Res. 2015;35:5525–32.PubMed
33.
Schwartz K, Chang HT, Nikolai M, Pernicone J, Rhee S, Olson K, et al. Treatment of glioma patients with ketogenic diets: report of two cases treated with an IRB-approved energy-restricted ketogenic diet protocol and review of the literature. Cancer Metab. 2015;3:3.PubMedPubMedCentralCrossRef
34.
Strowd RE, Cervenka MC, Henry BJ, Kossoff EH, Hartman AL, Blakeley JO. Glycemic modulation in neuro-oncology: experience and future directions using a modified Atkins diet for high-grade brain tumors. Neurooncol Pract. 2015;2:127–36.PubMedPubMedCentral
35.
Jansen N, Walach H. The development of tumours under a ketogenic diet in association with the novel tumour marker TKTL1: a case series in general practice. Oncol Lett. 2016;11:584–92.PubMed
36.
Klement RJ, Sweeney RA. Impact of a ketogenic diet intervention during radiotherapy on body composition: I. Initial clinical experience with six prospectively studied patients. BMC Res Notes. 2016;9:143.PubMedPubMedCentralCrossRef
37.
Artzi M, Liberman G, Vaisman N, Bokstein F, Vitinshtein F, Aizenstein O, et al. Changes in cerebral metabolism during ketogenic diet in patients with primary brain tumors: 1H-MRS study. J Neurooncol. 2017;132:267–75.PubMedCrossRef
38.
39.
Tisdale MJ, Brennan RA. A comparison of long-chain triglycerides and medium-chain triglycerides on weight loss and tumour size in a cachexia model. Br J Cancer. 1988;58:580–3.PubMedPubMedCentralCrossRef
40.
41.
Seyfried TN, Sanderson TM, El-Abbadi MM, McGowan R, Mukherjee P. Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. Br J Cancer. 2003;89:1375–82.PubMedPubMedCentralCrossRef
42.
Zhou W, Mukherjee P, Kiebish MA, Markis WT, Mantis JG, Seyfried TN. The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. Nutr Metab (Lond). 2007;4:5.CrossRef
43.
Freedland SJ, Mavropoulos J, Wang A, Darshan M, Demark-Wahnefried W, Aronson WJ, et al. Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. Prostate. 2008;68:11–9.PubMedPubMedCentralCrossRef
44.
Otto C, Kaemmerer U, Illert B, Muehling B, Pfetzer N, Wittig R, et al. Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides. BMC Cancer. 2008;8:122.PubMedPubMedCentralCrossRef
45.
Mavropoulos JC, Buschemeyer WC 3rd, Tewari AK, Rokhfeld D, Pollak M, Zhao Y, et al. The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. Cancer Prev Res. 2009;2:557–65.CrossRef
46.
Masko EM, Thomas JA 2nd, Antonelli JA, Lloyd JC, Phillips TE, Poulton SH, et al. Low-carbohydrate diets and prostate cancer: how Low Is “Low Enough”? Cancer Prev Res. 2010;3:1124–31.CrossRef
47.
Stafford P, Abdelwahab MG, Kim DY, Preul MC, Rho JM, Scheck AC. The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr Metab (Lond). 2010;7:74.CrossRef
48.
Maurer GD, Brucker DP, Bähr O, Harter PN, Hattingen E, Walenta S, et al. Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. BMC Cancer. 2011;11:315.PubMedPubMedCentralCrossRef
49.
Abdelwahab MG, Fenton KE, Preul MC, Rho JM, Lynch A, Stafford P, et al. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLoS ONE. 2012;7:e36197.PubMedPubMedCentralCrossRef
50.
Kim HS, Masko EM, Poulton SL, Kennedy KM, Pizzo SV, Dewhirst MW, et al. Carbohydrate restriction and lactate transporter inhibition in a mouse xenograft model of human prostate cancer. BJU Int. 2012;110:1062–9.PubMedPubMedCentralCrossRef
51.
Allen BG, Bhatia SK, Buatti JM, Cancer C, Published R, June O. Ketogenic diets enhance oxidative stress and radio-chemo-therapy responses in lung cancer Xenografts Ketogenic diets enhance oxidative stress and radio- chemo-therapy responses in lung cancer xenografts. Clin Cancer Res. 2013;19:3905–13.PubMedPubMedCentralCrossRef
52.
Caso J, Masko EM, Thomas JA II, Poulton SH, Dewhirst M, Pizzo SV, et al. The effect of carbohydrate restriction on prostate cancer tumor growth in a castrate mouse xenograft model. Prostate. 2013;73:449–54.PubMedCrossRef
53.
Poff AM, Ari C, Seyfried TN, Agostino DPD. The Ketogenic diet and hyperbaric oxygen therapy prolong survival in mice with systemic metastatic cancer. PLoS ONE. 2013;8:e65522.PubMedPubMedCentralCrossRef
54.
Husain Z, Huang Y, Seth P, Sukhatme VP. Tumor-derived lactate modifies antitumor immune response: effect on Myeloid-Derived suppressor cells and NK cells. J Immunol. 2014;191:1486–95.CrossRef
55.
Shukla SK, Gebregiworgis T, Purohit V, Chaika NV, Gunda V, Radhakrishnan P, et al. Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia. Cancer Metab. 2014;2:18.PubMedPubMedCentralCrossRef
56.
Zhuang Y, Chan DK, Haugrud AB, Miskimins WK. Mechanisms by which low glucose enhances the cytotoxicity of metformin to cancer cells both in vitro and in vivo. PLoS ONE. 2014;9:e108444.PubMedPubMedCentralCrossRef
57.
Gluschnaider U, Hertz R, Ohayon S, Smeir E, Smets M, Pikarsky E, et al. Long-chain fatty acid analogues suppress breast tumorigenesis and progression. Cancer Res. 2014;74:6991–7002.PubMedCrossRef
58.
Healy ME, Chow JDY, Byrne FL, Breen DS, Leitinger N, Li C, et al. Dietary effects on liver tumor burden in mice treated with the hepatocellular carcinogen diethylnitrosamine. J Hepatol. 2015;62:599–606.PubMedCrossRef
59.
Hao G-W, Chen Y-S, He D-M, Wang H-Y, Wu G-H, Zhang B. Growth of human colon cancer cells in nude mice is delayed by Ketogenic diet with or without Omega-3 fatty acids and medium-chain triglycerides. Asian Pac J Cancer Prev. 2015;16:2061–8.PubMedCrossRef
60.
Morscher RJ, Aminzadeh-Gohari S, Feichtinger RG, Mayr JA, Lang R, Neureiter D, et al. Inhibition of neuroblastoma tumor growth by Ketogenic Diet and/or calorie restriction in a CD1-Nu mouse model. PLoS ONE. 2015;10:e0129802.PubMedPubMedCentralCrossRef
61.
Poff AM, Ward N, Seyfried TN, Arnold P, D’Agostino DP. Non-toxic metabolic management of metastatic cancer in VM mice: novel combination of Ketogenic Diet, Ketone supplementation, and hyperbaric oxygen therapy. PLoS ONE. 2015;10:e0127407.PubMedPubMedCentralCrossRef
62.
Woolf EC, Curley KL, Liu Q, Turner GH, Charlton JA, Preul MC, et al. The Ketogenic Diet alters the hypoxic response and affects expression of proteins associated with angiogenesis, invasive potential and vascular permeability in a mouse glioma model. PLoS One. 2015;10:e0130357.PubMedPubMedCentralCrossRef
63.
Stemmer K, Zani F, Habegger KM, Neff C, Kotzbeck P, Bauer M, et al. FGF21 is not required for glucose homeostasis, ketosis or tumour suppression associated with ketogenic diets in Mice. Diabetologia. 2015;58:2414–23.PubMedPubMedCentralCrossRef
64.
Dang MT, Wehrli S, Dang CV, Curran T. The Ketogenic Diet does not affect growth of Hedgehog pathway Medulloblastoma in Mice. PLoS ONE. 2015;10:e0133633.PubMedPubMedCentralCrossRef
65.
Martuscello RT, Vedam-Mai V, McCarthy DJ, Schmoll ME, Jundi MA, Louviere CD, et al. A supplemented high-fat low-carbohydrate diet for the treatment of glioblastoma. Clin Cancer Res. 2016;22:2482–95.PubMedCrossRef
66.
Liśkiewicz AD, Kasprowska D, Wojakowska A, Polański K, Lewin-Kowalik J, Kotulska K, et al. Long-term high fat Ketogenic Diet promotes renal tumor growth in a rat model of Tuberous Sclerosis. Sci Rep. 2016;6:21807.PubMedPubMedCentralCrossRef
67.
Lussier DM, Woolf EC, Johnson JL, Brooks KS, Blattman JN, Scheck AC. Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic Ketogenic diet. BMC Cancer. 2016;16:10.CrossRef
68.
Xia S, Lin R, Jin L, Zhao L, Kang H-B, Pan Y, et al. Prevention of dietary-fat-fueled Ketogenesis attenuates BRAF V600E tumor growth. Cell Metab. 2017;25:358–73.PubMedCrossRef
69.
Allott EH, Macias E, Sanders S, Knudsen BS, Thomas G V, Hursting SD, et al. Impact of carbohydrate restriction in the context of obesity on prostate tumor growth in the Hi-Myc transgenic mouse model. Prostate Cancer Prostatic Dis. 2017;20:165–71.PubMedCrossRef
70.
Rieger J, Bähr O, Maurer GD, Hattingen E, Franz K, Brucker D, et al. ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol. 2014;44:1843–52.PubMedPubMedCentral
71.
Zahra A, Fath MA, Opat E, Mapuskar KA, Bhatia SK, Ma DC, et al. Consuming a Ketogenic Diet while receiving radiation and chemotherapy for locally advanced lung cancer and pancreatic cancer: The University of Iowa experience of two phase 1 clinical trials. Radiat Res. 2017;187:743–54.PubMedCrossRef
72.
Lv M, Zhu X, Wang H, Wang F, Guan W. Roles of caloric restriction, ketogenic diet and intermittent fasting during initiation, progression and metastasis of cancer in animal models: a systematic review and meta-analysis. PLoS ONE. 2014;9:e115147.PubMedPubMedCentralCrossRef
73.
74.
Fearon KC, Tisdale MJ, Preston T, Plumb JA, Calman KC. Failure of systemic ketosis to control cachexia and the growth rate of the Walker 256 carcinosarcoma in rats. Brit J Cancer. 1985;52:87–92.PubMedPubMedCentralCrossRef
75.
Beck SA, Tisdale MJ. Nitrogen excretion in cancer cachexia and its modification by a high fat diet in Mice. Cancer Res. 1989;49:3800–4.PubMed
76.
Otto C, Klingelhöffer C, Biggermann L, Melkus G, Mörchel P, Jürgens C, et al. Analysis of the metabolism of Ketone Bodies and lactate by gastrointestinal tumor cells in vitro. Aktuel Ernahrungsmed. 2014;39:51–9.CrossRef
77.
Hao G, Wang H, He D, Chen Y, Wu G, Zhang B. Effect of ketogenic diet on growth of human colon cancer cells in nude mice. Chinese J Clin Oncol. 2014;41:1154–7.
78.
Liu R-Q, Liu M-F, Jiang X-C, Guo Z-Z, Dong J-Y, Chen R, et al. Ketogenic diet affects tumor growth in the mouse model of EMT-6 breast cancer. Chinese J Cancer Prev Treat. 2015;22:827–31.
79.
De Feyter HM, Behar KL, Rao JU, Madden-Hennessey K, Ip KL, Hyder F, et al. A ketogenic diet increases transport and oxidation of ketone bodies in RG2 and 9L gliomas without affecting tumor growth. Neuro Oncol. 2016;18:1079–87.PubMedCrossRef
80.
Healy ME, Lahiri S, Hargett SR, Chow JDY, Byrne FL, Breen DS, et al. Dietary sugar intake increases liver tumor incidence in female mice. Sci Rep. 2016;6:22292.PubMedPubMedCentralCrossRef
81.
Brünings W. Beiträge zum Krebsproblem. 1. Mitteilung: Ueber eine diätetisch-hormonale Beeinflussung des Krebses. Münch Med Wschr. 1941;88:117–23.
82.
Brünings W. Beiträge zum Krebsproblem. 2. Mitteilung: Klinische Anwendungen der diätetisch-hormonalen Krebsbeeinflussung (“Entzuckerungsmethode”). Münch Med Wschr 1942; 89: 71–6.
83.
Schulte G, Schütz H. Insulin in der Krebsbehandlung. Münch Med Wschr. 1942;89:648–50.
84.
Zuccoli G, Marcello N, Pisanello A, Servadei F, Vaccaro S, Mukherjee P, et al. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: case report. Nutr Metab. 2010;7:33.CrossRef
85.
Moore K. Using the restricted ketogenic diet for brain cancer management: comments from neuro-oncologist. In: Seyfried TN, editor. Cancer as a metabolic disease: on the origin, management, and prevention of cancer. Hoboken: Wiley; 2012. p. 397–400.
86.
Fine EJ, Segal-isaacson CJ, Feinman RD, Herszkopf S, Romano MC, Tomuta N, et al. Targeting insulin inhibition as a metabolic therapy in advanced cancer: a pilot safety and feasibility dietary trial in 10 patients. Nutrition. 2012;28:1028–35.PubMedCrossRef
87.
Tóth C, Clemens Z. Halted progression of soft palate cancer in a patient treated with the paleolithic Ketogenic Diet alone. Am J Med Case Reports. 2016;4:288–92.
88.
Schwalb M, Taubmann M, Hines S, Reinwald H, Ruggiero M. Clinical observation of a novel, complementary, immunotherapeutic approach based on Ketogenic diet, chondroitin sulfate, vitamin D 3, oleic acid and a fermented milk and colostrum product. Am J Immunol. 2016;12:91–8.CrossRef
89.
Abdelbary M, Elsakka A, Salah H, Mokhtar W, Abdelzaher E. Does Metabolic management of gliomas using restricted Ketogenic diet combined with hyperbaric oxygen therapy (HBOT) improve clinical outcome and reduce epileptic risk? (poster presentation). Tampa: Metabolic Therapeutics Conference; 2017.
90.
Klement RJ. Restricting carbohydrates to fight head and neck cancer—is this realistic? Cancer Biol Med. 2014;11:145–61.PubMedPubMedCentral
91.
Warburg O, Posener K, Negelein E. Über den Stoffwechsel der Carcinomzelle. Biochem Zeitschr. 1924;152:309–43.
92.
Fine EJ, Miller A, Quadros EV, Sequeira JM, Feinman RD. Acetoacetate reduces growth and ATP concentration in cancer cell lines which over-express uncoupling protein 2. Cancer Cell Int. 2009;9:14.PubMedPubMedCentralCrossRef
93.
Seyfried TN, Shelton LM. Cancer as a metabolic disease. Nutr Metab (Lond). 2010;7:7.CrossRef
94.
Seyfried TN. Cancer as a metabolic disease: on the origin, management, and prevention of cancer. Hoboken: Wiley; 2012.CrossRef
95.
Marchut E, Gumińska M, Kedryna T. The inhibitory effect of various fatty acids on aerobic glycolysis in Ehrlich ascites tumour cells. Acta Biochim Pol. 1985;33:7–16.
96.
Nakahara W. Studies on Lymphoid activity. VI. Immunity to transplanted cancer induced by injection of olive oil. J Exp Med. 1921;35:493–505.CrossRef
97.
98.
Fine EJ, Feinman RD. Insulin, carbohydrate restriction, metabolic syndrome and cancer. Exp Rev Endocrin Metab. 2014;10:15–24.CrossRef
99.
Klement RJ, Fink MK. Dietary and pharmacological modification of the insulin/IGF-1 system: exploiting the full repertoire against cancer. Oncogenesis. 2016;5:e193.PubMedPubMedCentralCrossRef
100.
101.
Klement RJ, Sweeney RA. Impact of a ketogenic diet intervention during radiotherapy on body composition: II. Protocol of a randomised phase I study (KETOCOMP). Clin Nutr ESPEN. 2016;12:e1–6.PubMedCrossRef
102.
Ahmad IM, Aykin-Burns N, Sim JE, Walsh SA, Higashikubo R, Buettner GR, et al. Mitochondrial O2- and H2O2 Mediate glucose deprivation-induced stress in human cancer cells. J Biol Chem. 2005;280:4254–63.PubMedCrossRef
103.
Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, et al. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer. 2004;100:1179–85.PubMedCrossRef
104.
McGirt MJ, Chaichana KL, Gathinji M, Attenello F, Than K, Ruiz AJ, et al. Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas. Neurosurgery. 2008;63:286–91.PubMedCrossRef
105.
Derr RL, Ye X, Islas MU, Desideri S, Saudek CD, Grossman SA. Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009;27:1082–6.PubMedPubMedCentralCrossRef
106.
Lamkin DM, Spitz DR, Shahzad MMK, Zimmerman B, Lenihan DL, DeGeest K, et al. Glucose as a prognostic factor in Ovarian Carcinoma. Cancer. 2009;115:1021–7.PubMedPubMedCentralCrossRef
107.
Erickson K, Patterson RE, Flatt SW, Natarajan L, Parker BA, Heath DD, et al. Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer. J Clin Oncol. 2011;29:54–60.PubMedCrossRef
108.
Villarreal-Garza C, Shaw-Dulin R, Lara-Medina F, Bacon L, Rivera D, Urzua L, et al. Impact of diabetes and Hyperglycemia on survival in advanced breast cancer patients. Exp Diabetes Res. 2012;2012:732027.PubMedPubMedCentralCrossRef
109.
Minicozzi P, Berrino F, Sebastiani F, Falcini F, Vattiato R, Cioccoloni F, et al. High fasting blood glucose and obesity significantly and independently increase risk of breast cancer death in hormone receptor-positive disease. Eur J Cancer. 2013;49:3881–8.PubMedCrossRef
110.
Mayer A, Vaupel P, Struss H-G, Giese A, Stockinger M, Schmidberger H. Strong adverse prognostic impact of hyperglycemic episodes during adjuvant chemoradiotherapy of glioblastoma multiforme. Strahlenther Onkol. 2014;190:933–8.PubMedCrossRef
111.
Tieu MT, Lovblom LE, McNamara MG, Mason W, Laperriere N, Millar B-A, et al. Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide. J Neurooncol. 2015;124:119–26.PubMedPubMedCentralCrossRef
112.
Monzavi-Karbassi B, Gentry R, Kaur V, Siegel ER, Jousheghany F, Medarametla S, et al. Pre-diagnosis blood glucose and prognosis in women with breast cancer. Cancer Metab. 2016;4:7.PubMedPubMedCentralCrossRef
113.
Adeberg S, Bernhardt D, Foerster R, Bostel T, Koerber SA, Mohr A, et al. The influence of hyperglycemia during radiotherapy on survival in patients with primary glioblastoma. Acta Oncol (Madr). 2016;55:201–7.CrossRef
114.
Klement RJ, Champ CE. Corticosteroids compromise survival in glioblastoma in part through their elevation of blood glucose levels. Brain. 2017;140:e16.PubMed
115.
Fine EJ, Champ CE, Feinman RD, Márquez S, Klement RJ. An evolutionary and mechanistic perspective on dietary carbohydrate restriction in Cancer Prevention. J Evo Health. 2016;1:15.
116.
Clemens Z, Tóth C. Vitamin C and disease: insights from the evolutionary perspective. J Evo Health. 2016;1:13.
117.
Klement RJ, Feinman RD, Gross EC, Champ CE, D’Agostino DP, Fine EJ, et al. Need for new review of article on ketogenic dietary regimes for cancer patients. Med Oncol. 2017;34:108.PubMedCrossRef
118.
Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36:11–48.PubMedCrossRef
119.
Champ CE, Volek JS, Siglin J, Jin L, Simone NL. Weight Gain, metabolic syndrome, and breast cancer recurrence: are dietary recommendations supported by the data? Int J Breast Cancer. 2012;2012:506868.PubMedPubMedCentralCrossRef
120.
Gonder U. Article on ketogenic dietary regimes for cancer highly misleading. Med Oncol. 2017;34:109.PubMedCrossRef
121.
Cartwright N, Howick J. Evidence-based policy: where is our theory of evidence? J Child Serv. 2009;4:6–15.CrossRef
122.
Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides S, Pestell RG, Chiavarina B, et al. Ketones and lactate “fuel” tumor growth and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle. 2010;9:3506–14.PubMedPubMedCentralCrossRef
123.
Rodrigues LM, Uribe-Lewis S, Madhu B, Honess DJ, Stubbs M, Griffiths JR. The action of β-hydroxybutyrate on the growth, metabolism and global histone H3 acetylation of spontaneous mouse mammary tumours: evidence of a β- hydroxybutyrate paradox. Cancer Metab. 2017;5:4.PubMedPubMedCentralCrossRef
124.
125.
126.
Champ CE, Klement RJ. Commentary on “Strong adverse prognostic impact of hyperglycemic episodes during adjuvant chemoradiotherapy of glioblastoma multiforme”. Strahlenther Onkol. 2014;191:281–2.CrossRef
Metadata
Title
Beneficial effects of ketogenic diets for cancer patients: a realist review with focus on evidence and confirmation
Author
Rainer J. Klement
Publication date
01-08-2017
Publisher
Springer US
Published in
Medical Oncology / Issue 8/2017
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-017-0991-5

Other articles of this Issue 8/2017

Medical Oncology 8/2017 Go to the issue

Short Communication

Local and systemic immunity predict survival in patients with pulmonary sarcomatoid carcinoma

Original Paper

Validity of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 for resectable locally advanced gastric cancer

Short Communication

miR-181a-2 downregulates the E3 ubiquitin ligase CUL4A transcript and promotes cell proliferation

Original Paper

No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer

Original Paper

Impact of venous invasion on the efficacy of adjuvant chemotherapy in elderly patients with stage III colorectal cancer

Original Paper

Identification of a novel leukemic-specific splice variant of DNMT3B and its stability
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits